Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer

AT-101 is a BH3 mimetic and pan-Bcl-2 inhibitor that has shown potent anticancer activity in non-small-cell lung cancer (NSCLC) in murine models, but failed to show clinical efficacy when used in combination with docetaxel in NSCLC patients. Our recent study has demonstrated that AT-101 enhanced the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Tao, Shan, Jinlu, Li, Mengxia, Qing, Yi, Qian, Chengyuan, Wang, Guangjie, Li, Qing, Lu, Guoshou, Li, Chongyi, Peng, Yu, Luo, Hao, Zhang, Shiheng, Yang, Yuxing, Cheng, Yi, Wang, Dong, Zhou, Shu-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467754/
https://www.ncbi.nlm.nih.gov/pubmed/26089640
http://dx.doi.org/10.2147/DDDT.S82724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467754/
https://www.ncbi.nlm.nih.gov/pubmed/26089640
http://dx.doi.org/10.2147/DDDT.S82724

Ejemplares similares